Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics.
PSMA-targeted therapy
prostate cancer
theranostics
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
16
07
2019
accepted:
19
08
2019
pubmed:
28
8
2019
medline:
31
3
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has demonstrable value in guiding the management of the clinical evolution of prostatic cancer. The use of PSMA-targeted therapy using
Identifiants
pubmed: 31451487
pii: jnumed.119.234054
doi: 10.2967/jnumed.119.234054
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1504-1506Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.